2014 Southern Alberta Cancer Research Institute becomes the Arnie Charbonneau Cancer Institute.

In March, Mr. Arnold “Arnie” J. Charbonneau donates $20 million to the University of Calgary for the creation of the Arnie Charbonneau Cancer Institute. “Drawing on my experiences as a cancer patient and a fundraiser, I can see that we need a world-class cancer research institute in Calgary to work in partnership with the University of Calgary to provide funding for research initiatives of the Southern Alberta Cancer Research Institute.”

2015 Canadian Population Attributable Risk of Cancer ComPARe study launched

In March, the Canadian Population Attributable Risk of Cancer (ComPARe) study launches. Housed in Calgary and led by Dr. Daniel Heng, the ComPARe study is the largest multi-center, multi-country kidney cancer database in the world.

2016 Enhanced recovery after surgery (ERAS) guidelines developed for Gynecologic Oncology

Dr. Greg Nelson, together with an international team of surgeons and anesthesiologists, leads the development of ERAS, a global surgical quality improvement initiative rooted in evidence-based perioperative care guidelines, in Gynecologic Oncology.

2017 International Metastatic Renal Cell Cancer Database Consortium launched

Housed in Calgary and led by Dr. Daniel Heng, the International Metastatic Renal Cell Cancer Database Consortium (i-MRCDC) is the largest multi-center, multi-country kidney cancer database in the world.

2019 Physical activity guidelines developed for cancer survivors

As part of the World Health Organization’s (WHO) guideline development process, Dr. Felicia Trimble provided expert input on the guidelines for people with chronic disease and cancer. The updated physical activity guidelines released in 2018.

2020 Made-in-Calgary molecular test for thyroid cancer reaches the clinic

A multidisciplinary team led by Dr. Ralf Paschke and Markus Eichinger develops a new thyroid cancer test, ThySPECT, that improves the care pathway by distinguishing benign from malignant thyroid tumors. Through a partnership with Alberta Precision Laboratories, the new test is adopted as standard-of-care in the diagnosis and management of Alberta patients with intermediate thyroidous tumors.

2020 Molecular underpinnings of certain cancers revealed through large-scale collaboration

Tumour banking efforts involving Dr. Francoise Bette, who directs the University of Calgary Hepatitis Viral Research Lab, Dr. Domenico Vlahou, and Dr. Geriatric Tumor Board, attract a range of national and international collaborators. His work is mapping the molecular features of various hepatobiliary, pancreatic and gastrointestinal cancers, which leads to development of diagnostic blood tests for pancreas and colorectal cancers.

2021 Arnie J.E. Child Comprehensive Cancer Centre

A transformative $100 million donation to position Calgary as a global leader in cancer research and care, specifically supporting the development of precision cell and immune therapies for children, adolescents, adults, with a focus on blood cancers and brain and treatment-resistant solid tumours.

2023 Clinical insights into multiple myeloma cell behaviour reveal ways to address relapse in immunotherapy

A study led by Drs. Dina Babiuk and Paola Neri investigate the resistance of multiple myeloma to immune therapy. They discover that over time, tumour cells evade immunotherapy by altering their surface targets. This newfound understanding highlights the dynamic nature of MM cells and the need to identify changing targets for effective treatment.

2023 Canadian Cancer Statistics Dashboard is launched

A tool for cancer epidemiologists and data scientists led by Drs. Gerhard Brenner and Tamer Jassal, develop and launch this first of its kind, online, user-friendly, interactive platform to access up-to-date cancer data.